Silo Pharma (NASDAQ: SILO) announced that its wholly owned managed AI agent subsidiary, QwikAgents, has expanded its platform with support for customer-supplied NVIDIA API keys and the addition of Hermes agent runtime. The update makes NVIDIA the fifth supported bring-your-own-key provider, joining Anthropic, OpenAI, Google and DeepSeek. Customers can now use their own NVIDIA API keys to access NVIDIA Nemotron models, giving them greater control over model selection and cost management.
The addition of Hermes as an alternative to OpenClaw runtime allows customers to select either option when creating an AI agent. Both runtimes operate on QwikAgents infrastructure, which includes managed hosting, persistent memory, model routing and dedicated compute. This flexibility is significant because it lets enterprises choose the runtime that best fits their performance and compliance needs without changing their underlying infrastructure. For Silo Pharma, the move signals a strategic push into the rapidly growing AI agent market, diversifying its business beyond biopharmaceutical development.
The implications extend beyond a simple feature update. By supporting multiple bring-your-own-key providers, QwikAgents reduces vendor lock-in and appeals to cost-conscious and security-focused customers who want to leverage their existing NVIDIA agreements. NVIDIA's Nemotron models are designed for advanced reasoning and multimodal tasks, so adding support could attract developers building complex AI agents. The choice between Hermes and OpenClaw runtimes further differentiates QwikAgents in a crowded field, where managed infrastructure and ease of deployment are key selling points.
For investors, the announcement highlights Silo Pharma's dual focus: developing therapeutics for stress-induced psychiatric disorders, chronic pain and CNS diseases, while also operating a managed AI agent subsidiary. The company's pipeline includes SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The AI platform expansion could provide a new revenue stream and increase the company's visibility in the technology sector, though it remains a developmental-stage biopharmaceutical and cryptocurrency treasury company.
The full press release is available at https://ibn.fm/AXpqr. For ongoing updates on Silo Pharma, visit the company's newsroom at https://ibn.fm/SILO. The announcement was distributed through AINewsWire, a specialized communications platform focused on artificial intelligence advancements and one of more than 75 brands within the Dynamic Brand Portfolio at IBN. That network provides wire solutions through InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution and tailored corporate communications solutions. More information is available at www.AINewsWire.com, and full terms of use and disclaimers can be found at https://www.AINewsWire.com/Disclaimer.
